Tiragolumab
- Generic Name
- Tiragolumab
- Drug Type
- Biotech
- CAS Number
- 1918185-84-8
- Unique Ingredient Identifier
- 6XG22YQM2Z
- Background
Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)).
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 341
- Registration Number
- NCT03193190
- Locations
- 🇺🇸
Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
- Conditions
- Advanced/Metastatic Tumors
- Interventions
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 518
- Registration Number
- NCT02794571
- Locations
- 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.